Get access

Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta)

Authors

  • K. R. Kelly,

    Corresponding author
    1. Department of Primate Medicine, California National Primate Research Center, Davis, CA, USA
    • Dr Kristi Kelly, Primate Medicine, CNPRC, 1 Shields Avenue, Davis, CA 95616, USA. E-mail: krskelly@ucdavis.edu

    Search for more papers by this author
  • B. H. Pypendop,

    1. Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
    Search for more papers by this author
  • K. L. Christe

    1. Department of Primate Medicine, California National Primate Research Center, Davis, CA, USA
    2. Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA, USA
    Search for more papers by this author

Abstract

This study reports the pharmacokinetics of buprenorphine in conscious rhesus macaques (Macaca mulatta) after intravenous (i.v.) and intramuscular (i.m.) administration. Four healthy, opioid-naïve, socially housed, adult male macaques were used. Buprenorphine (0.03 mg/kg) was administered intravenously as a bolus or intramuscularly on separate occasions. Blood samples were collected prior to, and up to 24 h, postadministration. Serum buprenorphine concentrations were analyzed with liquid chromatography–mass spectrometry. Noncompartmental pharmacokinetic analysis was performed with commercially available software. Mean residence time in the i.v. study as compared to the i.m. study was 177 (159–189) vs. 185 (174–214) min, respectively [median (range)]. In the i.v. study, concentration back-extrapolated to time zero was found to be 33.0 (16.8–57.0) ng/mL [median (range)]. On the other hand, the maximum serum concentration found in the i.m. study was 11.8 (6.30–14.8) ng/mL [median (range)]. Rhesus macaques maintained concentrations >0.10 ng/mL for over 24 h in the i.v. study and over 12 h in the i.m. study. Bioavailability was found to be 68.1 (59.3–71.2)% [median (range)]. No significant adverse effects were observed in the monkeys at the 0.03 mg/kg dose of buprenorphine during either study.

Get access to the full text of this article

Ancillary